What Bank of Cyprus Oncology Centre does

Bank of Cyprus Oncology Centre is a specialised oncology hospital located in Strovolos, Nicosia, Cyprus, operating as a private not-for-profit-style centre within the country's General Healthcare System (GHS). Founded in 1998 with its Clinical Trials Unit established in 1999, the centre serves Cypriot cancer patients across all disease stages via three integrated clinical departments — Medical Oncology, Radiation Oncology & Nuclear Medicine, and Diagnostic & Interventional Radiology — supported by inpatient wards (up to 32 daily), a Day Care Unit, Outpatient Department, Supportive Care Unit, Palliative Care (since 2009), Psychological Support, Dietician services, a Cancer Genetics Clinic, and an on-site oncology pharmacy with a Central Drugs Dilution Unit (Clean Room) for chemotherapy preparation.

The centre's technology stack centres on comprehensive cancer care delivery rather than a proprietary software platform. Notable operational features include pharmacist-verified chemotherapy protocols, a clean-room drug dilution unit with safety cabinets, and the A.G. Leventis Clinical Trials Unit which has run phase I–IV trials continuously since 1999. The centre is co-founded with the Cyprus Centre for Cancer Research (CCRI), holds CHKS accreditation and ISO 9001 certification, and participates in the EU eCAN Plus Joint Action for digital oncology. In 2025 it piloted the AI-powered Prognostic ultrasound-imaging platform with the German Oncology Center, and in December 2025 it experienced a cybersecurity breach that is under investigation by the Digital Security Authority and the Office of the Commissioner for Personal Data Protection.

Revenue is generated primarily through Cyprus GHS state reimbursement (chemotherapy drugs free for eligible Cypriot patients), supplemented by private fees from non-eligible patients, outpatient pharmacy dispensing fees (€6 registration + up to €10 health stamps), and contract revenue from pharmaceutical-sponsored clinical trials. The centre is expanding to a new Larnaca-Famagusta facility scheduled for summer 2026. Revenue figures are not publicly disclosed.

Name

Bank of Cyprus Oncology Centre

Legal name

Bank of Cyprus Oncology Centre

Website

https://bococ.org.cy

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

Bank of Cyprus Oncology Centre is a Cypriot specialised oncology hospital in Nicosia offering comprehensive cancer care — chemotherapy, radiotherapy, diagnostics, palliative and supportive care — reimbursed primarily through the national General Healthcare System, with a clinical trials unit operating since 1999.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Cancer treatment services
• Oncology care
• Radiation therapy
• Chemotherapy services
• Clinical trials

Headquarters

HQ city

Strovolos

HQ country

Cyprus

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Government Healthcare System Reimbursement: The centre is a public healthcare provider that receives reimbursement through Cyprus's General Healthcare System (GHS) and state hospital funding arrangements for eligible Cypriot patients. Chemotherapy drugs are provided free of charge to Cypriot cancer patients.
2. Private Patient Fees: Non-eligible patients (those not covered under GHS) pay for services including doctor visits, diagnostic tests, and treatments according to the centre's fee schedule.
3. Clinical Trial Contracts: The centre conducts industry-sponsored clinical trials (phases I-IV) under contract with pharmaceutical companies and international contract research organisations. Regular on-site inspections are carried out by contractor organisations.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Bank of Cyprus Oncology Centre is a specialized oncology hospital in Nicosia, Cyprus operating three main clinical departments: Medical Oncology, Radiation Oncology & Nuclear Medicine, and Diagnostic & Interventional Radiology. It provides comprehensive cancer care across all stages including diagnosis, chemotherapy, radiotherapy, nuclear medicine, palliative care, psychological support, dietary services, and clinical trial participation via the A.G. Leventis Clinical Trials Unit.

Product overview

Bank of Cyprus Oncology Centre is a specialized oncology hospital operating three main clinical departments: Medical Oncology, Radiation Oncology & Nuclear Medicine, and Diagnostic & Interventional Radiology. The centre offers a comprehensive range of cancer care services including inpatient and outpatient treatment, chemotherapy preparation and administration, radiotherapy, palliative care, psychological support, dietary services, and a clinical trials unit. The centre also provides supportive care for managing treatment side effects and operates a pharmacy specialized in oncology medications. A new Larnaca-Famagusta facility is planned for 2026 to expand care coverage.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology (Παθολογία Ογκολογίας) Comprehensive medical oncology services for cancer treatment including chemotherapy administration, hormone therapy, and immunotherapy for cancer patients in Cyprus.
• Radiation Oncology & Nuclear Medicine (Ακτινοθεραπευτική Ογκολογία & Πυρηνική Ιατρική) Radiotherapy and nuclear medicine treatments for cancer patients, including external beam radiation and radiopharmaceutical therapies.
• Diagnostic & Interventional Radiology (Διαγνωστική & Επεμβατική Ακτινολογία) Advanced diagnostic imaging and interventional radiology procedures for cancer diagnosis and treatment guidance.
• Cancer Genetics Clinic (Κλινική Γενετικής του Καρκίνου) Genetic testing and counseling services for hereditary cancer risk assessment and family screening.
• Day Care Unit (Μονάδα Ημερήσιας Φροντίδας) Outpatient treatment facility for chemotherapy and other treatments that do not require overnight hospitalization.
• Outpatient Department (Τμήμα Εξωτερικών Ιατρείων) Outpatient clinics providing consultations, follow-up care, and outpatient treatments for cancer patients.
• Inpatient Department (Wards) (Τμήμα Εσωτερικών Ασθενών) Hospitalization services with up to 32 patients daily for treatments, managing side effects, and dealing with disease complications.
• Supportive Care Unit (Τμήμα Υποστηρικτικής Φροντίδας) Urgent care for oncology patients to treat chemotherapy side effects (thrombocytopenia, neutropenia, gastrointestinal and electrolyte disturbances) and radiotherapy side effects (stomatitis, pain).
• Pharmacy (Φαρμακείο) Oncology pharmacy services including chemotherapy preparation in a central drugs dilution unit, dispensing of oral and injectable chemotherapy, and medication counseling.
• Palliative Care (Ανακουφιστική Φροντίδα) Holistic approach to patient care focusing on pain control, symptom management, and psychosocial and spiritual support for patients and families.
• Psychological Support/Counselling (Ψυχολογική Υποστήριξη) Individual and family counseling sessions with a clinical psychologist to help patients and relatives cope with the emotional impact of cancer diagnosis and treatment.
• Dietician (Κλινικός Διαιτολόγος) Nutritional counseling and diet planning services for cancer patients to support treatment and recovery.
• A.G. Leventis Clinical Trials Unit Clinical trials unit conducting phases I-IV clinical trials since 1999, providing patients access to experimental treatments and contributing to cancer research.

Quantifiable outcome

• Clinical trials have been conducted for over 26 years, from 1999 to present, across phases I-IV at national and global level.
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• eCAN Plus ConsortiumcoreStrategic or Co-development Partner · 1 May 2025The centre participates in the EU Joint Action eCAN Plus (Enhancing Digital Capabilities of Cancer Centres in Europe), a flagship EU project (EU4Health Programme) involving 81 organisations from 23 European countries. The initiative aims to test and pilot safe integration of digital tools and health data across cancer centres, improve cross-border health data exchange, and strengthen collaboration among cancer centres. Project runs from May 2025 to April 2029.
• German Oncology CentercoreStrategic or Co-development PartnerClinical partner in pilot testing of Prognostic, an AI-powered oncology platform that analyses tumour stiffness from ultrasound imaging to predict patient response to cancer treatment. Testing conducted on breast and pancreatic cancer preclinical models.
• CCRI (Cyprus Centre for Cancer Research)coreStrategic or Co-development PartnerCCRI is listed as a founding partner of the Bank of Cyprus Oncology Centre on the centre's website, indicating a long-standing strategic and research collaboration relationship.
• Cyprus Anti-Cancer SocietyminorStrategic or Co-development PartnerThe centre collaborates with patient support associations including the Cyprus Anti-Cancer Society for psychosocial support referrals and patient services. Collaboration with cancer association drivers is noted for prescription drug collection.
• Digital Security Authority (Cyprus)minorOthersFollowing the data breach detected on 1 December 2025, the centre notified and is cooperating with the Digital Security Authority (DSA) for investigation and incident response.
• Office of the Commissioner for Personal Data Protection (Cyprus)minorOthersThe centre is cooperating with the Office of the Commissioner for Personal Data Protection following the data breach investigation, as required by data protection regulations.
• Horizon Europe Funding ProgrammeminorStrategic or Co-development PartnerThe Prognostic AI platform project aims to pursue national and European funding through Horizon Europe over the next 12-18 months for clinical validation and hospital pilots.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• European Institute of Oncology (IEO): Specialized cancer hospital in Milan, Italy, founded by Umberto Veronesi, integrating medical oncology, radiotherapy, surgery, and clinical research. Closely comparable European specialty oncology model with academic-style research mission.
• King Hussein Cancer Center: Specialty standalone cancer hospital in Amman, Jordan, treating Middle East patient populations with comprehensive oncology services including clinical trials. Comparable integrated specialty cancer center in a similar regional Mediterranean/Middle Eastern context.
• German Oncology Center: Specialty oncology center in Limassol, Cyprus, providing medical oncology, radiotherapy and related cancer care. Direct peer in the same domestic market with overlapping service lines; recently partnered with Bank of Cyprus Oncology Centre on the Prognostic AI pilot.

Broad incumbents

• Sheba Medical Center - Tel HaShomer: Israel's largest hospital with a comprehensive cancer center, clinical research institute, and digital health initiatives. Comparable in delivering advanced oncology care and clinical trials in the Eastern Mediterranean.
• Karolinska Comprehensive Cancer Center: Sweden's academic comprehensive cancer center within Karolinska University Hospital, conducting phase I-IV clinical trials and integrated oncology care. Comparable in combining university-grade research with clinical delivery.
• Gustave Roussy: Leading European comprehensive cancer center near Paris, combining inpatient oncology care, clinical research (phases I-IV), and AI/digital health initiatives. Comparable integrated research-clinical model at much larger scale.
• MD Anderson Cancer Center: World-leading comprehensive cancer center in Houston, Texas, integrating medical oncology, radiation oncology, research, and clinical trials. Comparable integrated care + research model at the largest global scale.
• Christie NHS Foundation Trust: Largest single-site cancer center in Europe (Manchester, UK), operating as a dedicated oncology hospital with extensive clinical trials program. Comparable dedicated cancer hospital model, although much larger and publicly funded.

Regional players

• Aretaeio Hospital: Private multi-specialty hospital in Nicosia, Cyprus, offering oncology services among other specialties. Comparable as a domestic private healthcare competitor serving the same Cypriot patient population.
• Acibadem Healthcare Group: Major Turkish private hospital group with comprehensive oncology centers serving domestic and medical tourism patients. Comparable private operator delivering integrated specialty care in the broader Eastern Mediterranean region.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/bank-of-cyprus-oncology-centre

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bank of Cyprus Oncology Centre